



Restriction Map of ptTS-Neo Vector. Unique restriction sites are in bold.

Description

The ptTS-Neo Vector is an expression vector designed to express the tetracycline-controlled transcriptional suppressor (tTS). The tTS is a fusion of the Tet repressor protein (TetR) and the KRAB-AB silencing domain of the Kid-1 protein (SD^{Kid-1}), a powerful transcriptional suppressor (1, 2). In the *absence* of Dox, tTS binds to the *tetO* sequences in the modified Tet-responsive promoter (P_{TREmod}) of a Tet response plasmid (pSIREN-RetroQ-TetH or pSIREN-RetroQ-TetP) and blocks expression of the shRNA. As Dox is added to the culture medium, the tTS dissociates from the P_{TREmod} , relieving transcriptional suppression. ptTS-Neo also contains a bacterial origin of replication and *E. coli* Amp^r gene for propagation and selection in bacteria, as well as a neomycin^r gene for the selection of stable transformants.

Use

The ptTS-Neo Vector is used to develop stable Tet tTS cell lines. ptTS-Neo is designed to deliver and express the regulatory protein tTS. After a pSIREN-RetroQ-Tet vector—containing an inserted shRNA under the control of $P_{TREmod/U6}$ —is transfected into a Tet tTS cell line, the tTS binds to the P_{TREmod} , repressing transcription in the absence of tetracycline (Tc) or its derivative doxycycline (Dox). As Tc or Dox is added to the culture medium, the tTS dissociates from the P_{TREmod} and transcription of the shRNA is turned on in a highly dose-dependent manner. More information on pSIREN-RetroQ-Tet vectors and protocols describing the construction of Tet tTS cell lines can be found in the BD™ Knockout Inducible RNAi Systems User Manual (PT3810-1).

BD Biosciences

Clontech
Discovery Labware
Immunocytometry Systems
Pharmingen



United States
800.662.2566

Canada
888.259.0187

Europe
32.53.720.211

Japan
81.3.5324.9609

Asia Pacific
65.6861.0633

Latin America/Caribbean
55.11.5185.9995

BD Biosciences Clontech
1020 East Meadow Circle
Palo Alto, CA 94303-4230
Technical Support (US)
E-mail: tech@clontech.com
www.bdbiosciences.com

(PR4X801; published 12 November 2004)

Location of Features

- Fragment containing SV40 promoter: 8–326
- Neomycin resistance gene (Neo^r): 361–1155
- Fragment containing thymidine kinase poly A: 1158–1328
- Cytomegalovirus (CMV) immediate early promoter (P_{CMV}): 1516–2189
- Tetracycline-controlled transcriptional suppressor (tTS): 2217–3057
- Fragment containing β -globin poly A: 2852–4014
- Col E1ori (Site of replication initiation): 4378–5021
- Ampicillin resistance gene (β -lactamase): 6029–5169
Start codon (ATG): 6029–6027 stop codon (TAA): 5171–5169

Sequencing Primer Locations

- tTS Seq/PCR Primers:
tTS-1 (6368–6386): 5'-TGACGTCTAAGAAACCA-3'
tTS-3 (2133–2152): 5'-GACGCCATCCACGCTGTT-3'

Selection of Stable Transfectants

- Selectable marker: plasmid confers resistance to G418 (400 μ g/ml).

Propagation in *E. coli*

- Suitable host strains: DH5 α , DH10B, and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (100 μ g/ml) in *E. coli* hosts.
- *E. coli* replication origin: ColE1
- Copy number: low

References

1. Freundlieb S., Schirra-Muller, C. & Bujard, H. (1999) *J. Gene Med.* **1**(1):4–12.
2. Witzgall R., O'Leary, E., Leaf, A., Onaldi, D. & Bonventre, J. (1994) *Proc. Natl. Acad. Sci. USA* **91**(10):4514–4518.

Note: The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with sequences obtained by BD Biosciences – Clontech. This vector has not been completely sequenced.

Notice to Purchaser

This product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes nor is it intended for human use. BD Biosciences – Clontech products may not be resold, modified for resale, or used to manufacture commercial products without written approval of BD Biosciences – Clontech.

Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. patents No. 5,464,758 and No. 5,814,618 which are proprietary to TET Systems Holding GmbH & Co KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems Holding GmbH & Co KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kinds as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems Holding GmbH & Co KG prior to purchasing these reagents or using them for any purpose. BD Biosciences – Clontech is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression systems to TET Systems Holding GmbH & Co KG. For license information, please contact:

IP Merchandisers GmbH & Co KG
Im Neuenheimer Feld 582
69120 Heidelberg
Germany
Telephone: +49 (0)6221 5 88 04 00
Fax: +49 (0)6221 5 88 04 04
Web: www.tetsystems.com/

The CMV promoter is covered under U.S. Patent Nos. 5,168,062, and 5,385,839 assigned to the University of Iowa Research Foundation. BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2004 BD